<DOC>
	<DOCNO>NCT01109940</DOCNO>
	<brief_summary>This study design extension study proof-of-concept trial CAIN457A2209 patient moderate severe ankylose spondylitis aim provide continuous treatment AIN457 patient core trial , obtain safety tolerability information . The study address evaluation efficacy follow dos 3 mg/kg AIN457 give every 4 week period initially 6 month ( Part 1 ) base risk/benefit balance AIN457 ankylose spondylitis decision take continue dose another 6 month period ( Part 2 ) .</brief_summary>
	<brief_title>Safety Tolerability AIN457 Adults ( 18-65 Years ) With Moderate Severe Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>A diagnosis ankylose spondylitis Patients take part core CAIN457A2209 study Patients continue treatment AIN457 consider appropriate treating physician . Patients noncompliant demonstrate major protocol deviation core CAIN457A2209 study . Patients discontinue core CAIN457A2209 study Visit 14 ( Week 16 ) , patient complete core study discontinue core study 2 week baseline visit . Pregnant lactate woman Presence active infection Positive PPD HIV test patient repeat test deem appropriate due risk profile Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>IgG1K monoclonal antibody</keyword>
	<keyword>Interleukin -17A neutralize</keyword>
</DOC>